Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure.
Kawano N, Wada H, Uchiyama T, Kawasugi K, Madoiwa S, Takezako N, Suzuki K, Seki Y, Ikezoe T, Hattori T, Okamoto K. Kawano N, et al. Among authors: takezako n. Thromb J. 2020 Feb 7;18:2. doi: 10.1186/s12959-020-0216-6. eCollection 2020. Thromb J. 2020. PMID: 32047363 Free PMC article.
Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa.
Kawasugi K, Wada H, Honda G, Kawano N, Uchiyama T, Madoiwa S, Takezako N, Suzuki K, Seki Y, Ikezoe T, Iba T, Okamoto K. Kawasugi K, et al. Among authors: takezako n. Thromb J. 2021 Feb 25;19(1):12. doi: 10.1186/s12959-021-00264-z. Thromb J. 2021. PMID: 33632246 Free PMC article.
An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection.
Madoiwa S, Honda G, Kawano N, Uchiyama T, Kawasugi K, Takezako N, Suzuki K, Seki Y, Ikezoe T, Okamoto K, Wada H. Madoiwa S, et al. Among authors: takezako n. Int J Lab Hematol. 2021 Dec;43(6):1566-1574. doi: 10.1111/ijlh.13643. Epub 2021 Jul 6. Int J Lab Hematol. 2021. PMID: 34228395
Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment-A Cohort Study Using a Postmarketing Surveillance Database.
Yoshinobu S, Honda G, Kawano N, Uchiyama T, Kawasugi K, Madoiwa S, Takezako N, Takayuki I, Wada H. Yoshinobu S, et al. Among authors: takezako n. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211054094. doi: 10.1177/10760296211054094. Clin Appl Thromb Hemost. 2021. PMID: 34870471 Free PMC article.
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators. Tauchi T, et al. Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10. Leuk Res. 2011. PMID: 21145591
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y; DADI Trial Group. Kimura S, et al. Among authors: takezako n. Lancet Haematol. 2020 Mar;7(3):e218-e225. doi: 10.1016/S2352-3026(19)30235-2. Epub 2020 Jan 21. Lancet Haematol. 2020. PMID: 31978329 Clinical Trial.
HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR.
Sakai K, Kuwana M, Tanaka H, Hosomichi K, Hasegawa A, Uyama H, Nishio K, Omae T, Hishizawa M, Matsui M, Iwato K, Okamoto A, Okuhiro K, Yamashita Y, Itoh M, Kumekawa H, Takezako N, Kawano N, Matsukawa T, Sano H, Ohshiro K, Hayashi K, Ueda Y, Mushino T, Ogawa Y, Yamada Y, Murata M, Matsumoto M. Sakai K, et al. Among authors: takezako n. Blood. 2020 Jun 25;135(26):2413-2419. doi: 10.1182/blood.2020005395. Blood. 2020. PMID: 32253422 Free article.
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K. Ozaki S, et al. Among authors: takezako n. Blood Cancer J. 2015 Sep 18;5(9):e349. doi: 10.1038/bcj.2015.79. Blood Cancer J. 2015. PMID: 26383822 Free PMC article. No abstract available.
97 results